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THE ROLE of the sympathetic nervous system in human essential hypertension and in animal models of essential hypertension remains controversial despite intensive study for many years. A major ap- VOL. 45, No. 2, AUGUST 1979 to nerve growth factor (immunosympathectomy; Levi-Montalcini and Angeletti, 1966) or 6-hydroxydopamine (Angeletti and Levi-Montalcini, 1970) . The chemical sympathectomy produced by the neonatal administration of 6-hydroxydopamine also has the disadvantage of producing marked effects on central noradrenergic neurons (Clark et al., 1972; Jacks et al., 1972) , and hence, it does not produce a strictly peripheral sympathectomy. Both methods produce permanent sympathectomy only when administered to neonates.
Over the last few years, we have systematically characterized ) the permanent chemical sympathectomy produced in rats by the chronic administration of guanethidine to neonatal or adult rats (Jensen-Holm and Juul, 1971; Burnstock et al., 1971; Eranko and Eranko, 1971) . We have shown that the sympathectomy is superior to that caused by previously used methods in that: (1) functional innervation of the vasculature is destroyed in the neonate and reduced by about 90% in rats treated as adults (as determined in pithed rat preparations); (2) there are no discernible transient or permanent effects on central noradrenergic neurons; and (3) this sympathectomy is achieved with little or no mortality or growth deficit in the Sprague-Dawley (S-D) rat.
Having characterized (in S-D rats) this model of sympathectomy, we proceeded to apply the method to spontaneously hypertensive rats (SHR, Okomoto strain). Our objectives were to determine the effect of sympathectomy in neonates (prior to development of hypertension) and adults (after hypertension is developed) on the hypertension in these rats. Unexpectedly, we found that SHR are resistant to guanethidine-induced chemical sympathectomy, a resistance not shared by normal Wistar and Kyoto Wistar rats. An essentially complete sympathectomy was achieved by adding a small amount of nerve growth factor (NGF) antiserum to the treatment regimen in neonatal rats.
Methods

Treatment of Animals
Pregnant S-D or American Wistar rats were obtained from commerical suppliers (Zivic-Miller and Charles River, respectively). SHR and Kyoto Wistar rats were obtained from the National Institutes of Health and bred in this laboratory. SHR were brother/sister mated. Neonates were treated as previously described by subcutaneous injection of guanethidine sulfate, 50 mg/kg per day (kindly supplied by Ciba), 5 days per week for 3 weeks starting at 7 days of age. Adult SHR (9-14 weeks) were treated with 40 mg/kg per day, 5 days/week for 5 weeks .
The biochemical studies were carried out on rats killed by decapitation. Tissues were removed, rinsed in iced saline, blotted dry, and frozen on dry ice. Norepinephrine (NE) was assayed in tissues homogenized in 3-5 ml of cold 0.4 N HC1O<. After centrifugation, catecholamines were adsorbed onto alumina at pH 8.2-8.4 and eluted into 2 ml of 0.1 N acetic acid. NE was determined by the trihydroxyindole method as described by Chang (1964) .
Tyrosine hydroxylase (TOH) activity was determined as described by Mueller et al. (1969) (Tables  2 and 4) or by a minor modification of the method described by Phillipson and Sandier (1975) (Table  7) . Final concentrations of 40 fiM tyrosine and 825 M DMPH4 were used. Assays were carried out under conditions linear with time and enzyme concentration. Protein was measured by the method of Lowry et al. (1951) .
Experiments to evaluate functional innervation of the vasculature were done by measuring the response to stimulation of the sympathetic vasomotor outflow in the pithed rat preparation (Gillespie and Muir, 1967) . Rats were anesthetized with sodium pentobarbital (35 mg/kg, ip) and the trachea, jugular vein, and carotid artery were cannulated. Blood pressure and heart rate were recorded via the carotid artery by means of a Statham pressure transducer and recorded on a Grass polygraph or Beckman dynagraph.
Bilateral adrenalectomy was performed via an abdominal incision and the abdomen closed with wound clips. The rats were allowed to stabilize, and blood pressure and heart rate were recorded. The rats were then artificially respired (Harvard rodent respirator) with room air and were pithed through an orbit of the eye with a steel rod. After pithing, the rats were administered rf-tubocurarine (1.2 mg/ kg, iv) and atropine sulfate (1.5 mg/kg, iv) to block somatic and parasympathetic outflows, respectively. The blood pressure rise elicited by stimulation of the vasomotor outflow was determined by stimulating the steel rod with a Grass stimulator with supramaximal rectangular pulses (60 V, 1 msec in duration) of increasing frequency for 20 seconds. Three to 5 minutes were allowed between each stimulation.
Guanethidine accumulation in ganglia was determined in neonatal animals treated with 50 mg/kg per day as described above. Ganglia were removed and assayed for guanethidine content by a fluorometric method based on the formation of a phenanthrenequinone derivative (Johnson and Hunter, in press ).
Antibody to NGF was prepared by injecting NGF prepared by the method of Bocchini and Angeletti (1969) (kindly supplied by Dr. Ralph Bradshaw) into foot pads of New Zealand rabbits (1 mg protein in 50% saline-50% complete Freunds adjuvant) with periodic boosting. Rabbits were bled and sera obtained. Sera were bioassayed in the classical dorsal root ganglion assay (Levi-Montalcini et al., 1954) . All sera used obliterated the response of 1 BU of NGF at a dilution of 1/1000 or greater. Anti-NGF was administered (0.2-0.3 ml sc) to rats on the 4th day of each treatment week (i.e., days 11, 18, and 25 of age).
Analysis of the statistical significance of differences between treated and control groups were by Student's t-test (two-tailed). In Tables 6 and 7 , comparisons among the four groups were made by the analysis of variance followed by multiple comparisons using the Scheffe test for variables showing homogeniety of variance with Bartlett's test (Blood pressure, Table 6 ).
For the other variables (heart rate, Table 6 ; Table  7 ), a logarithmic transformation failed to produce homogeneity of variances. Therefore, the KruskalWallis rank test, which is not dependent on this assumption or the normality assumption, was used with multiple comparisons made by the appropriate formula (Gibbons, 1976) .
Results
Neonatal SHR were treated with guanethidine using a protocol which previously had been shown to produce an essentially complete sympathectomy of S-D rats. Unexpectedly, guanethidine-treated SHR showed no evidence of functional denervation of vasculature as assessed in the pithed rat preparation (Fig. 1) . Similar increases in pressure in response to nerve stimulation were seen in treated and control rats. Raising the dose of guanethidine and extending the treatment did not result in functional denervation ( Because of the striking difference in the response of S-D rats and SHR to the guanethidine treatment, other strains of rats were examined. Treatment of neonatal Kyoto Wistar rats, the parent strain of the SHR, resulted in a complete abolition of the response to stimulation of vasomotor outflow (Fig. 2) . Similarly, guanethidine treatment produced functional denervation of the vasculature in Wistar rats obtained from an American supplier (Charles River) (data not shown). In all cases, rats were assessed at 10-12 weeks of age; that is, 6-8 weeks after the last injection of guanethidine. Hence, the SHR is the only strain of rat tested that was resistant to guanethidine. The data in Table 1 show the effect of neonatal guanethidine treatment on the mean arterial pressures in pentobarbital-anesthetized adult rats (at least 10 weeks old) of the four strains. Guanethidine treatment resulted in a decrease in blood pressure in all four strains. The decrease in the SHR (7%) was much smaller than the decrease (18-26%) seen in the other strains.
Two biochemical parameters were used to assess the degree of sympathectomy produced by guaneth- ' Rats were treated as described in Methods with daily doses (mg/kg) of guanethidine (guan) shown in parenthe Rats were killed at 10-13 weeks of age.
f Each value represents the mean ± SEM of number of observations shown in parentheses.
idine in the four strains of rats. TOH activity was assessed as an indication of the number of viable neurons in sympathetic ganglia. Whereas TOH activity in the superior cervical ganglia was reduced by more than 86% in S-D, Kyoto Wistar, and American Wistar rats, the enzyme activity was reduced by only 50-75% in the ganglia of SHR (Table 2) . These enzyme activities are consistent with the differences in the size of the ganglia. At dissection, the ganglia of the guanethidine-treated SHR were only moderately reduced in size, whereas the ganglia of the other strains were reduced to small nodules. Analysis of NE levels in heart and spleen (Table 3) was consistent with the enzyme data. Neonatal guanethidine treatment reduced NE levels by 95% or more in all strains except SHR in which tissue NE was reduced by only about 75-80%. Hence, guanethidine produces a complete biochemical and functional sympathectomy in S-D, Kyoto Wistar, and American Wistar rats, but only a partial sympathectomy is achieved in SHR. Guanethidine is unique among agents which destroy sympathetic neurons in that cytotoxic effects also are seen in animals treated as adults. 6-Hydroxydopamine destroys nerve terminals, but not cell perikarya, and, hence, regeneration rapidly occurs. In contrast to the dramatic effects of chronic treatment in adult S-D rats , adult SHR are resistant to guanethidine. Adult SHR were treated with guanethidine for 5 weeks and the status of the sympathetic nervous system evaluated 4-5 weeks after stopping treatment. The increase in blood pressure resulting from stimulation of the vasomotor outflow in pithed rats was only slightly reduced (Fig. 3) . This is in contrast to the 90% decrease in response seen in S-D rats . Likewise, the biochemical parameters are reduced only by 40-50% (Table 4) . Heart NE was reduced by 48% as compared to reduction to undetectable levels in S-D rats. Ganglionic TOH was reduced only by 43% as compared to an 85% decrease in S-D rats ). An obvious possibility to explain resistance to 
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FIGURE 3 Response (mean ± SEM) to stimulation of the vasomotor outflow in adrenalectomized pithed SHR treated as adults with saline (control) or guanethidine (as described in Methods). Initial mean arterial blood pressures were: control (211 ± 15 mm Hg) and guanethidine (200 ±11 mm Hg). There was no statistical difference in the response of treated and control groups except at 1 Hz(P< 0.05).
guanethidine-induced chemical sympathectomy in the SHR would be that guanethidine does not accumulate in the ganglia of SHR to attain concentrations reached in the ganglia of the other strains of rats. This does not appear to be the case. Guanethidine concentration was determined in superior cervical ganglia 24 hours after the last of three daily injections of guanethidine (50 mg/kg per day). Guanethidine reaches maximal levels after two injections (Johnson and Hunter, in press ). The concentration (Table 5) was not statistically different in ganglia of SHR or Kyoto Wistar rats. Because the cytotoxic effects of guanethidine on sympathetic neurons can be prevented by concomitant administration of NGF (Johnson and Aloe, 1974) , we asked if the addition of small amounts of antibody of NGF (anti-NGF), combined with guanethidine, would lead to a complete sympathectomy in SHR. To the standard guanethidine treatment of neonatal SHR, a small amount (0.2-0.3 ml) of NGF antisera was added on the 4th day of each treatment week (i.e., day 11, 18, and 25 of age). The results of these experiments are shown in Figure 4 and Tables 6 and 7. The evaluation of functional innervation of the vasculature in pithed rats 15 " 7-day-old rats were treated with guanethidine (50 mg/kg per day) for three injections. Rats were killed 24 hours after last injection (11 days old), ganglia removed, and guanethidine determined as described in Methods. Each value is the mean ± SEM of three samples of three pairs each.
f Kyoto Wistar rats and SHR (11 days old) were killed, superior cervical ganglia removed, and protein content determined by the Lowry (15) method. Each value is the mean ± SEM of number of rats shown in parentheses.
shown in Figure 4 . In contrast to the results seen in Figure 1 , the guanethidine treatment alone produced a modest (about 50%) decrease in response to stimulation. Anti-NGF alone produced a similar decrease in response. The combined treatment of guanethidine and anti-NGF produced an almost complete functional denervation of the vasculature. The effects of the various treatments on blood pressure and heart rate in pentobarbital anesthetized SHR, before and after acute adrenalectomy, are shown in Table 6 . Consistent with earlier results (Table 1) , neonatal guanethidine treatment lowered blood pressure only slightly. Likewise, anti-NGF lowered pressure only slightly. The combined treatment, however, lowered blood pressure to nonhypertensive levels. The blood pressure dropped markedly after acute adrenalectomy, indicating that under these experimental conditions adrenal catecholamines are of major importance in the maintenance of the elevated blood pressure. Again, only in animals receiving combined anti-NGF/guanethidine did the blood pressure fall to a level lower than that in untreated rats.
The significantly more complete sympathectomy, produced by combined guanethidine/anti-NGF treatment over either agent alone, also is shown by the analysis of TOH in sympathetic ganglia (Table 7) . In contrast to guanethidine or anti-NGF alone, either of which reduces TOH activity in superior cervical ganglia by about 50-60%, the combined treatment reduced TOH activity by more than 90%, thereby indicating a sympathectomy similar to that produced by guanethidine alone in the other strains. Similar reductions in TOH activity were produced in celiac ganglia. Table 6 .
Discussion
The deficiencies of currently existing methods of sympathectomy, as described in the introduction, suggested that the guanethidine-induced chemical sympathectomy would provide a means of unambiguously assessing the requirement for peripheral sympathetic nervous function in the development and maintenance of hypertension in the SHR. Experiments carried out to test this idea produced the unexpected observation that SHR are uniquely resistant to the sympathectomy produced by guanethidine. In our initial experiments (Fig. 1) , we found that guanethidine produced no functional impairment of the innervation of the vasculature and only a partial sympathectomy assessed by biochemical criteria. Other strains of rats, including Kyoto Wistar, were uniformly sensitive to guanethidine. The sympathectomy produced in these other strains was entirely consistent with those in our previous reports on S-D rats.
The resistance of the SHR to guanethidine does not appear related to failure of the neurons in the SHR to accumulate guanethidine. Raising the dose of guanethidine or prolonging treatment does not improve the sympathectomy. Direct chemical analysis shows no difference in the level of guanethidine in ganglia of treated SHR or Kyoto Wistar rats. Also, administration of a cytotoxic guanethidine analog, which accumulates to a concentration twice that of guanethidine, also fails to sympathectomize SHR completely, whereas S-D rats are completely sympathectomized (unpublished observation).
Hence, it appears that there is a distinct difference in the neurons of the SHR that allows these neurons to tolerate better high concentrations of guanethidine.
We previously have reported that the cytotoxic effects of guanethidine on sympathetic neurons can be prevented by the concomitant administration of NGF (Johnson and Aloe, 1974) . Speculating that perhaps there is an excess of NGF in SHR or that SHR are particularly sensitive to NGF that antagonizes the action of guanethidine, we attempted to determine if low doses of anti-NGF would augment the cytotoxicity of guanethidine. The results obtained show that combined guanethidine/anti-NGF treatment produced an essentially complete functional and biochemical sympathectomy, and in the absence of a sympathetic nervous system, hypertension failed to develop in the SHR. Although the biochemical results obtained in the initial and later experiments are quite consistent (Table 2 and Table  7) , differences were noted with respect to functional sympathectomy produced by guanethidine alone (Figs. 1 and 4) . The reason for this is not clear. The initial experiment (Fig. 1) showing no functional deficit was carried out on a small group of animals, whereas the later experiment (Fig. 4) showing a modest decrease in function involved larger numbers of rats. These experiments were carried out almost 3 years apart, and some change in the colony may have occurred. This is also suggested by the fact that we have observed, in our earlier experiments (late 1974) , that guanethidine was well tolerated by SHR, but in later experiments (1977, early 1978) , guanethidine produced significant weight loss and mortality in SHR but not in S-D rats. In any event, the level of hypertension in the colony has been constant over the span of the study, and the rats are clearly resistant to guanethidine. Consistent with other reports, deprivation of peripheral sympathetic function, under conditions in which CNS neurons are unaltered, reduces or prevents the development of hypertension in the Okomoto SHR (Follkow et al., 1972; Cutilletta et al., 1977) . The mechanism underlying the unique resistance of the SHR to guanethidine-induced hypertension is not clear. Although our rationale for the combined use of guanethidine and anti-NGF was a possible "enhanced" NGF system in SHR, our data are insufficient to provide a strong argument for such a phenomenon. A much more systematic study, using various doses of the agents and involving other strains of rats, would be required to demonstrate synergism as opposed to additive effects. It does, however, suggest the possibility that some anomaly of the NGF response, either peripherally or centrally, may play a role in the enhanced sympathetic nervous activity which appears to participate in the development of hypertension in the SHR.
